1. Home
  2. NXE vs GKOS Comparison

NXE vs GKOS Comparison

Compare NXE & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nexgen Energy Ltd.

NXE

Nexgen Energy Ltd.

HOLD

Current Price

$11.97

Market Cap

6.2B

Sector

N/A

ML Signal

HOLD

Logo Glaukos Corporation

GKOS

Glaukos Corporation

HOLD

Current Price

$123.75

Market Cap

6.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NXE
GKOS
Founded
2011
1998
Country
Canada
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.2B
6.3B
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
NXE
GKOS
Price
$11.97
$123.75
Analyst Decision
Strong Buy
Analyst Count
0
14
Target Price
N/A
$127.71
AVG Volume (30 Days)
7.2M
677.3K
Earning Date
03-03-2026
02-17-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$469,820,000.00
Revenue This Year
N/A
$31.33
Revenue Next Year
N/A
$24.01
P/E Ratio
N/A
N/A
Revenue Growth
N/A
30.38
52 Week Low
$3.91
$73.16
52 Week High
$12.19
$163.71

Technical Indicators

Market Signals
Indicator
NXE
GKOS
Relative Strength Index (RSI) 77.72 67.79
Support Level $11.06 $93.96
Resistance Level $11.33 $115.00
Average True Range (ATR) 0.49 4.80
MACD 0.15 0.26
Stochastic Oscillator 90.06 97.69

Price Performance

Historical Comparison
NXE
GKOS

About NXE Nexgen Energy Ltd.

NexGen Energy Ltd is an exploration and development entity engaged in acquiring, evaluating, and developing uranium properties in Canada. The company's projects portfolio consists of ROOK I, and the IsoEnergy, at the Athabasca Basin.

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Share on Social Networks: